GDS Holdings is rated Neutral due to a balanced risk-reward profile driven by strong demand for AI infrastructure and Alibaba exposure, offset by significant challenges such as negative free cash flow, high capital expenditures, and a large debt burden of RMB 4.2 billion. While EBITDA growth is slower than move-in rates due to legacy contracts and pricing pressures, capital spending exceeds organic operating cash flow. The stock trades at a forward EBITDA multiple of 10.6x, below peers, reflecting caution over limited return on investment visibility and pending asset monetization. Investors await GDS's Q3 2026 results, expected later this month, amid a generally bullish consensus.
GDS Holdings and its Q3 2026 preview provide context for the Technology sector's performance on Pluang as of Nov 10, 2026 20:03 WIB. Of 150 priced Technology-sector US stocks tradable on Pluang, 40 rose and 101 fell today. Notable movers include QUBT at USD 6.45 with a 1-day change of -5.98% and Pluang order activity showing 98% Sell, IONQ at USD 33.30 down 5.77% with 70% Sell activity, and AXTI at USD 40.62 down 5.34% with 57% Sell activity. The most notable figure is QUBT's 98% Sell order activity.
project44 has partnered with Snowflake to enhance supply chain decision-making through Mo, an AI-powered supply chain analyst. Mo uses project44's extensive logistics data and Snowflake Cortex AI to provide accurate, consistent answers to complex sup...
H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...
Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...
Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...
Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...
